Abstract:Rapamycin is an immunosuppressant that has been shown to prevent tumor growth following organ transplantation. However, its exact mode of antitumor action remains unknown. The present study used the B16‐F10 (B16) murine melanoma model to explore the antitumor mechanism of rapamycin, and it was revealed that rapamycin reduced B16 cell viability in vitro and in vivo . In addition, in vitro and in vivo , the results of western blotting showed that rapamycin reduced Bcl2 expression, and enhanced the protein expression levels of cleaved caspase 3 and Bax, indicating that it can induce the apoptosis of B16 melanoma cells. Furthermore, the results of cell cycle analysis and western blotting showed that rapamycin induced B16 cell cycle arrest in the G 1 phase, based on the reduction in the protein expression levels of CDK1, cyclin D1 and CDK4, as well as the increase in the percentage of cells in G 1 phase. Rapamycin also significantly increased the number of autophagosomes in B16 melanoma cells, as determined by transmission electron microscopy. Furthermore, the results of RT‐qPCR and western blotting showed that rapamycin upregulated the protein expression levels of microtubule‐associated protein light chain 3 (LC3) and Beclin‐1, while downregulating the expression of p62 in vitro and in vivo , thus indicating that rapamycin could trigger cellular autophagy. The present study revealed that rapamycin in combination with chloroquine (CQ) further increased LC3 expression compared with that in the CQ group, suggesting that rapamycin induced an increase in autophagy in B16 cells. Furthermore, the results of western blotting showed that rapamycin blocked the phosphorylation of p70 ribosomal S6 kinase (p70‐S6k) and mammalian target of rapamycin (mTOR) proteins in vitro and in vivo , thus suggesting that rapamycin may exert its antitumor effect by inhibiting the phosphorylation of the mTOR/p70‐S6k pathway. In conclusion, rapamycin may inhibit tumor growth by inducing cellular G1 phase arrest and apoptosis. In addition, rapamycin may exert its antitumor effects by inducing the autophagy of B16 melanoma cells in vitro and in vivo , and the mTOR/p70‐S6k signaling pathway may be involved in this process.

43-O-(β-d-glucoside)-rapamycin, a Microbial Conversion Product by Bacillus Subtilis CGMCC7764

14-deoxorapamycin, the microbial conversion product of rapamycin by Micromonospora chersina FIM03-712

Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization.

Sirolimus bioconversion by Bacillus megaterium

Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis

Synthesis and Anticancer Activity of Novel Rapamycin C-28 Containing Triazole Moiety Compounds

Comparative Metabolic Profiling-Based Improvement of Rapamycin Production by Streptomyces Hygroscopicus

Insights into the Metabolic Mechanism of Rapamycin Overproduction in the Shikimate-Resistant Streptomyces Hygroscopicus Strain Uv-Ii Using Comparative Metabolomics

Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used As Potential Mtor‐targeted Anticancer Agents

Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids As Mtor Targeted Anti-cancer Agents

7-O-ethyl-rapamycin produced by rapamycin producing strain mutant FC904-107

Comparative Metabolic Profiling Reveals the Key Role of Amino Acids Metabolism in the Rapamycin Overproduction by Streptomyces Hygroscopicus

Enhancement of Rapamycin Production by Metabolic Engineering in Streptomyces Hygroscopicus Based on Genome-Scale Metabolic Model

Isolation and identification of rapamycin dialdehyde

Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis.

Coupled cell morphology investigation and metabolomics analysis improves rapamycin production in Streptomyces hygroscopicus

Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‐S6k pathway

Isolation, Structure Determination and Biological Activity of 15-Deoxo-7,32-o-didesmethylrapamycin from the Soil Actinomycete Ll-D45042

Structural Characterization and Antitumor Activity of a Polysaccharide from Ramulus Mori.

Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity

Hyper-Synergistic Antifungal Activity of Rapamycin and Peptide-Like Compounds against Candida albicans Orthogonally via Tor1 Kinase